Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430442 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,026
- Enrollment target
NCT01430442 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,026 participants.
The verdict
NCT01430442, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,026 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an optimal dose to support the Phase 3 clinical trials.
Interventions
- DRUG Placebo
- DRUG Rimegepant
- DRUG Sumatriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,026 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430442
The ClinicalTrials.gov registry entry for NCT01430442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,026 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01430442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01430442 about?
NCT01430442 is a clinical study titled "Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine". The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, m...
What is the current status of trial NCT01430442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,026 participants. The study started on 2011-10. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01430442?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG), Sumatriptan (DRUG).
Who is sponsoring clinical trial NCT01430442?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.